Skip to main navigation Skip to search Skip to main content

Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial

  • Soo Heon Kwak
  • , Kyung Ah Han
  • , Kyung Soo Kim
  • , Jae Myung Yu
  • , Eun Sook Kim
  • , Jong Chul Won
  • , Jun Goo Kang
  • , Choon Hee Chung
  • , Seungjoon Oh
  • , Sung Hee Choi
  • , Kyu Chang Won
  • , Sin Gon Kim
  • , Seung Ah Cho
  • , Bo Young Cho
  • , Kyong Soo Park

    Research output: Contribution to journal › Article › peer-review

    22   Link opens in a new tab Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial'. Together they form a unique fingerprint.
    Sort by

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science